These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16686808)

  • 21. Initiatives to control drug costs associated with an independent physician association.
    Abourjaily P; Kross J; Gouveia WA
    Am J Health Syst Pharm; 2003 Feb; 60(3):269-72. PubMed ID: 12613237
    [No Abstract]   [Full Text] [Related]  

  • 22. Prescription drugs: issues of cost, coverage, and quality.
    Copeland C
    EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of satisfaction of health plan members with prescription drug benefits.
    Motheral BR; Heinle SM
    Am J Health Syst Pharm; 2004 May; 61(10):1007-14. PubMed ID: 15160776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physician strategies to reduce patients' out-of-pocket prescription costs.
    Alexander GC; Casalino LP; Meltzer DO
    Arch Intern Med; 2005 Mar; 165(6):633-6. PubMed ID: 15795338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What Strategies Do Physicians and Patients Discuss to Reduce Out-of-Pocket Costs? Analysis of Cost-Saving Strategies in 1,755 Outpatient Clinic Visits.
    Hunter WG; Zhang CZ; Hesson A; Davis JK; Kirby C; Williamson LD; Barnett JA; Ubel PA
    Med Decis Making; 2016 Oct; 36(7):900-10. PubMed ID: 26785714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Real-time Prescription Benefit Recommendations on Patient Out-of-Pocket Costs: A Cluster Randomized Clinical Trial.
    Desai SM; Chen AZ; Wang J; Chung WY; Stadelman J; Mahoney C; Szerencsy A; Anzisi L; Mehrotra A; Horwitz LI
    JAMA Intern Med; 2022 Nov; 182(11):1129-1137. PubMed ID: 36094537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
    Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
    JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Approaches to pharmacy benefit management and the impact of consumer cost sharing.
    Olson BM
    Clin Ther; 2003 Jan; 25(1):250-72. PubMed ID: 12637125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Out-of-Pocket Costs for Advanced Imaging Across the US Private Insurance Marketplace.
    Rosenkrantz AB; Sadigh G; Carlos RC; Silva E; Duszak R
    J Am Coll Radiol; 2018 Apr; 15(4):607-614.e1. PubMed ID: 29477290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization.
    Motheral B; Fairman KA
    Med Care; 2001 Dec; 39(12):1293-304. PubMed ID: 11717571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.
    Soumerai SB; Avorn J; Ross-Degnan D; Gortmaker S
    N Engl J Med; 1987 Aug; 317(9):550-6. PubMed ID: 3302713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The utility of cost discussions between patients with cancer and oncologists.
    Zafar SY; Chino F; Ubel PA; Rushing C; Samsa G; Altomare I; Nicolla J; Schrag D; Tulsky JA; Abernethy AP; Peppercorn JM
    Am J Manag Care; 2015 Sep; 21(9):607-15. PubMed ID: 26618364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physician communication about the cost and acquisition of newly prescribed medications.
    Tarn DM; Paterniti DA; Heritage J; Hays RD; Kravitz RL; Wenger NS
    Am J Manag Care; 2006 Nov; 12(11):657-64. PubMed ID: 17090222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of multitiered copayments on the use and cost of prescription drugs among Medicare beneficiaries.
    Gilman BH; Kautter J
    Health Serv Res; 2008 Apr; 43(2):478-95. PubMed ID: 18370964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managing psychotropic drug costs: will formularies work?
    Huskamp HA
    Health Aff (Millwood); 2003; 22(5):84-96. PubMed ID: 14515884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving physicians' knowledge of the costs of common medications and willingness to consider costs when prescribing.
    Korn LM; Reichert S; Simon T; Halm EA
    J Gen Intern Med; 2003 Jan; 18(1):31-7. PubMed ID: 12534761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medicare: looking for pareto optimal changes.
    Christensen S
    Inquiry; 1992; 29(4):426-39. PubMed ID: 1473866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incentive-based formularies.
    Thomas CP
    N Engl J Med; 2003 Dec; 349(23):2186-8. PubMed ID: 14657424
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.